Merck has characterized its cost-cutting initiative as more of a reallocation of resources to support other, higher-growth ...

Drug maker Merck announced Tuesday it will embark on an initiative to cut $3 billion in costs 2027, including an undisclosed ...

Merck (MRK) announced a bold cost-cutting strategy aiming to save $3 billion annually by 2027, reflecting a major operational ...

Merck & Co., Inc. (NYSE: MRK) is one of the most undervalued blue chip stocks to buy according to hedge funds. On July 21, ...

Merck, a pharmaceutical company headquartered in Rahway, announced it will be undergoing layoffs after a disappointing second ...

Merck's Q2 2025 earnings call reveals revenue of $15.8B, strategic growth plans with a $3B reinvestment initiative, and confidence in driving ...

CEO Rob Davis referred to the cost reduction program as a 'reallocation' rather than a cut, with the savings to be reinvested ...

Merck did not immediately respond to a request for comment on the job cuts. The company expects the program to cost about $3 billion to implement but would lead to $3 billion in annual cost savings by ...

Merck has launched a sweeping cost-cutting effort designed to save $3 billion annually by the end of 2027, the company said ...

The multi-year effort comes as Merck prepares to offset revenue losses from the upcoming patent expiration of its blockbuster cancer drug Keytruda.

Torrent Pharmaceuticals seeks CCI approval for acquiring J B Chemicals in a ₹19,500-crore deal, becoming India's second most valued pharma company.